BAPREXIV Trademark

Trademark Overview

On Thursday, January 8, 2015, a trademark application was filed for BAPREXIV with the United States Patent and Trademark Office. The USPTO has given the BAPREXIV trademark a serial number of 86498850. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, November 12, 2018. This trademark is owned by Pfizer Inc.. The BAPREXIV trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, genetic immunological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations for use in hematology; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations, smoking cessation preparations, and tissue repair preparations; vaccines for human use
baprexiv

General Information

Serial Number86498850
Word MarkBAPREXIV
Filing DateThursday, January 8, 2015
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, November 12, 2018
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 11, 2015

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, genetic immunological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations for use in hematology; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations, smoking cessation preparations, and tissue repair preparations; vaccines for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, January 21, 2015
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10017
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Tuesday, November 13, 2018ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, November 12, 2018ABANDONMENT - NO USE STATEMENT FILED
Wednesday, February 21, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, February 20, 2018EXTENSION 5 GRANTED
Tuesday, February 6, 2018EXTENSION 5 FILED
Tuesday, February 6, 2018TEAS EXTENSION RECEIVED
Saturday, September 9, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, September 7, 2017EXTENSION 4 GRANTED
Thursday, September 7, 2017EXTENSION 4 FILED
Thursday, September 7, 2017TEAS EXTENSION RECEIVED
Wednesday, March 1, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, February 27, 2017EXTENSION 3 GRANTED
Monday, February 27, 2017EXTENSION 3 FILED
Monday, February 27, 2017TEAS EXTENSION RECEIVED
Tuesday, September 13, 2016NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 12, 2016EXTENSION 2 GRANTED
Wednesday, August 17, 2016EXTENSION 2 FILED
Friday, September 9, 2016CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, August 17, 2016TEAS EXTENSION RECEIVED
Friday, March 11, 2016NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, March 9, 2016EXTENSION 1 GRANTED
Wednesday, March 9, 2016EXTENSION 1 FILED
Wednesday, March 9, 2016TEAS EXTENSION RECEIVED
Tuesday, October 6, 2015NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, August 11, 2015OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 11, 2015PUBLISHED FOR OPPOSITION
Wednesday, July 22, 2015NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Saturday, July 4, 2015LAW OFFICE PUBLICATION REVIEW COMPLETED
Tuesday, June 30, 2015ASSIGNED TO LIE
Sunday, June 14, 2015APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, June 12, 2015TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, June 11, 2015CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, June 11, 2015TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, March 7, 2015NOTIFICATION OF NON-FINAL ACTION E-MAILED
Saturday, March 7, 2015NON-FINAL ACTION E-MAILED
Saturday, March 7, 2015NON-FINAL ACTION WRITTEN
Friday, March 6, 2015ASSIGNED TO EXAMINER
Wednesday, January 21, 2015NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, January 12, 2015NEW APPLICATION ENTERED IN TRAM

Related Keywords

baprexiv preparations pharmaceutical dysfunction treatment cancer diabetes sexual pain disorders diseases